Seroba and Kurma Partners Announce Complementary Series B Funding for Vico Therapeutics totaling €65.8 million ($70.7 million)
Seroba, a European life sciences venture capital firm headquartered in Dublin, with offices in Paris and Milan, and Kurma Partners, a key European Venture Capital firm financing innovation in Healthcare and Biotechnology, from pre-seed to growth capital, based in Paris and Munich, announced today the completion of the second closing part of Series B financing round of Vico Therapeutics. Vico …